Melissa Armstrong

Melissa Armstrong, MD, MSc, FAAN

Associate Professor Of Neurology, Director, Mangurian Clinical-Research Headquarters For Lewy Body Dementia

Department: MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone: (352) 273-5550

About Melissa Armstrong

Dr. Melissa J. Armstrong, MD, MSc is the Director of the Mangurian Clinical-Research Headquarters for Lewy Body Dementia at the University of Florida. She joined the UF Department of Neurology in 2015.

Dr. Armstrong graduated from Illinois Wesleyan University in 1995 with a major in chemistry and a minor in philosophy. She completed medical school at the Stritch School of Medicine (Loyola University Chicago), where she subsequently completed a preliminary residency year in internal medicine and her neurology residency. Following her residency, she worked as a general neurologist at Loyola University Medical Center before pursuing fellowship training in movement disorders. Dr. Armstrong was a clinical and research fellow at the highly respected Morton & Gloria Shulman Movement Disorders Centre in Toronto, Ontario (Canada) from 2008 through 2011 where she was an Edmond J. Safra Fellow in Movement Disorders. She also completed an MSc in clinical epidemiology and health care research at the University of Toronto Institute for Health Policy Management and Evaluation. Dr. Armstrong worked as an assistant professor in the Division of Movement Disorders at the University of Maryland from 2012 until moving to the University of Florida in 2015. During this time, she co-authored the book, “Parkinson’s Disease: Improving Patient Care” (Oxford American Neurology Library 2014). She was also recognized as part of the American Academy of Neurology’s Emerging Leaders Forum (2013-2014). In addition to her work in the field of movement disorders, she serves as an evidence-based medicine methodology consultant for the American Academy of Neurology, working on their clinical practice guideline development program.

At the University of Florida, Dr. Armstrong directs the Mangurian Clinical-Research Headquarters for Lewy Body Dementia, one of 25 centers in the United States recognized as a Lewy Body Dementia Association Research Center of Excellence (2017 to current). She also serves on the Lewy Body Dementia Association Scientific Advisory Council. Dr. Armstrong’s Lewy body dementia research focuses on the lived experience of disease for individuals with Lewy body dementia and their families, ranging from patient and caregiver priorities for care to hospital outcomes to end-of-life experiences.

Accomplishments

Faculty Clinical Research Award
2016 · University of Florida Department of Neurology
Golden Hammer Award
2015 · University of Maryland Department of Neurology
American Academy of Neurology Emerging Leader
2013 · American Academy of Neurology

Board Certifications

  • Neurology
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties
  • Neurology
Areas of Interest
  • Dementia
  • Parkinson disease

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-2163-1907

Publications

2021
Advances in dementia with Lewy bodies
Therapeutic Advances in Neurological Disorders. 14 [DOI] 10.1177/17562864211057666.
2021
Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts.
Alzheimer disease and associated disorders. 35(1):55-61 [DOI] 10.1097/WAD.0000000000000414. [PMID] 33009039.
2021
Clinical Care and Unmet Needs of Individuals With Dementia With Lewy Bodies and Caregivers: An Interview Study.
Alzheimer disease and associated disorders. 35(4):327-334 [DOI] 10.1097/WAD.0000000000000459. [PMID] 34034295.
2021
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Journal of managed care & specialty pharmacy. 27(6):785-790 [DOI] 10.18553/jmcp.2021.27.6.785. [PMID] 34057395.
2021
Frequency of suicidal ideation and associated clinical features in Lewy body dementia
Parkinsonism & Related Disorders. 90:33-37 [DOI] 10.1016/j.parkreldis.2021.07.029.
2021
Impact of Off Periods on Persons With Parkinson Disease and Care Partners: A Qualitative Study.
Neurology. Clinical practice. 11(3):e232-e238 [DOI] 10.1212/CPJ.0000000000000921. [PMID] 34484896.
2021
Informal caregiver experiences at the end-of-life of individuals living with dementia with Lewy bodies: An interview study
Dementia. [DOI] 10.1177/14713012211038428.
2021
Outcome Measures for Dementia With Lewy Body Clinical Trials: A Review.
Alzheimer disease and associated disorders. [DOI] 10.1097/WAD.0000000000000473. [PMID] 34393189.
2021
Patient values in healthcare decision making among diverse older adults.
Patient education and counseling. [DOI] 10.1016/j.pec.2021.08.031. [PMID] 34509339.
2021
Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset.
Journal of geriatric psychiatry and neurology. [DOI] 10.1177/08919887211023586. [PMID] 34114509.
2021
Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study
BMJ Open. 11(5) [DOI] 10.1136/bmjopen-2020-047554. [PMID] 34039578.
2021
Response to Telemedicine Visits From Patients With Parkinsonism During the COVID-19 Pandemic on Postvisit Surveys.
Journal of patient experience. 8 [DOI] 10.1177/2374373521997224. [PMID] 34179388.
2021
Suicide and Lewy body dementia: Report of a Lewy body dementia association working group
International Journal of Geriatric Psychiatry. 36(3):373-382 [DOI] 10.1002/gps.5462.
2021
The inconsistency and instability of Parkinson’s disease motor subtypes.
Parkinsonism & related disorders. 88:13-18 [DOI] 10.1016/j.parkreldis.2021.05.016. [PMID] 34091412.
2021
Treatment of Parkinson’s Disease with Cognitive Impairment: Current Approaches and Future Directions
Behavioral Sciences. 11(4) [DOI] 10.3390/bs11040054. [PMID] 33920698.
2020
An evidence-based methodology for systematic evaluation of clinical outcome assessment measures for traumatic brain injury
PLOS ONE. 15(12) [DOI] 10.1371/journal.pone.0242811. [PMID] 33315925.
2020
Assessment of Parkinson disease quality measures on 12-month patient outcomes.
Neurology. Clinical practice. 10(1):58-64 [DOI] 10.1212/CPJ.0000000000000745. [PMID] 32190421.
2020
Caregiver-Reported Barriers to Quality End-of-Life Care in Dementia With Lewy Bodies: A Qualitative Analysis
American Journal of Hospice and Palliative Medicine®. 37(9):728-737 [DOI] 10.1177/1049909119897241. [PMID] 31902223.
2020
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction.
Frontiers in human neuroscience. 14 [DOI] 10.3389/fnhum.2020.583441. [PMID] 33240065.
2020
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.
Alzheimer's research & therapy. 12(1) [DOI] 10.1186/s13195-020-00703-5. [PMID] 33121510.
2020
Choosing a Parkinson Disease Treatment.
JAMA. 323(14) [DOI] 10.1001/jama.2020.1224. [PMID] 32286645.
2020
Common neurodegenerative disorders in the perioperative setting: Recommendations for screening from the Society for Perioperative Assessment and Quality Improvement (SPAQI)
Perioperative Care and Operating Room Management. 20 [DOI] 10.1016/j.pcorm.2020.100092. [PMID] 32577538.
2020
Dementia with Lewy bodies and Parkinson disease dementia: More different than similar?
Neurology. 94(20):858-859 [DOI] 10.1212/WNL.0000000000009433. [PMID] 32332128.
2020
Diagnosis and Treatment of Parkinson Disease: A Review.
JAMA. 323(6):548-560 [DOI] 10.1001/jama.2019.22360. [PMID] 32044947.
2020
Ethnoracial Differences in Lewy Body Diseases with Cognitive Impairment.
Journal of Alzheimer's disease : JAD. 77(1):165-174 [DOI] 10.3233/JAD-200395. [PMID] 32804137.
2020
Experience and Impact of OFF Periods in Parkinson’s Disease: A Survey of Physicians, Patients, and Carepartners.
Journal of Parkinson's disease. 10(1):315-324 [DOI] 10.3233/JPD-191785. [PMID] 31815702.
2020
How do guideline developers identify, incorporate and report patient preferences? An international cross-sectional survey.
BMC health services research. 20(1) [DOI] 10.1186/s12913-020-05343-x. [PMID] 32448198.
2020
How to identify, incorporate and report patient preferences in clinical guidelines: A scoping review
Health Expectations. 23(5):1028-1036 [DOI] 10.1111/hex.13099. [PMID] 32656807.
2020
Parkinson disease with mild cognitive impairment: Domain-specific cognitive complaints predict dementia.
Acta neurologica Scandinavica. 142(6):585-596 [DOI] 10.1111/ane.13326. [PMID] 32740919.
2020
Participation and consultation engagement strategies have complementary roles: A case study of patient and public involvement in clinical practice guideline development
Health Expectations. 23(2):423-432 [DOI] 10.1111/hex.13018. [PMID] 31884708.
2020
Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 94(9):392-404 [DOI] 10.1212/WNL.0000000000009033. [PMID] 32051244.
2020
Research priorities of caregivers and individuals with dementia with Lewy bodies: An interview study
PLOS ONE. 15(10) [DOI] 10.1371/journal.pone.0239279. [PMID] 33027276.
2020
Time for a New Image of Parkinson Disease.
JAMA neurology. 77(11):1345-1346 [DOI] 10.1001/jamaneurol.2020.2412. [PMID] 32716484.
2019
Author response: Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research.
Neurology. 92(24) [DOI] 10.1212/WNL.0000000000007669. [PMID] 31182516.
2019
Barriers and facilitators of communication about off periods in Parkinson’s disease: Qualitative analysis of patient, carepartner, and physician Interviews
PLOS ONE. 14(4) [DOI] 10.1371/journal.pone.0215384. [PMID] 30998707.
2019
Cause of Death and End-of-Life Experiences in Individuals with Dementia with Lewy Bodies
Journal of the American Geriatrics Society. 67(1):67-73 [DOI] 10.1111/jgs.15608.
2019
Causes and outcomes of hospitalization in Lewy body dementia: A retrospective cohort study
Parkinsonism & Related Disorders. 64:106-111 [DOI] 10.1016/j.parkreldis.2019.03.014.
2019
Cognitive Complaints in Nondemented Parkinson’s Disease Patients and Their Close Contacts do not Predict Worse Cognitive Outcome.
Alzheimer disease and associated disorders. 33(2):147-153 [DOI] 10.1097/WAD.0000000000000301. [PMID] 30958414.
2019
Communication About OFF Periods in Parkinson’s Disease: A Survey of Physicians, Patients, and Carepartners
Frontiers in Neurology. 10 [DOI] 10.3389/fneur.2019.00892. [PMID] 31481924.
2019
Developing the Disorders of Consciousness Guideline and Challenges of Integrating Shared Decision-Making Into Clinical Practice.
The Journal of head trauma rehabilitation. 34(3):199-204 [DOI] 10.1097/HTR.0000000000000496. [PMID] 31058760.
2019
End-of-life experiences in dementia with Lewy bodies: Qualitative interviews with former caregivers
PLOS ONE. 14(5) [DOI] 10.1371/journal.pone.0217039. [PMID] 31145749.
2019
Improving patient‐centred care for persons with Parkinson’s: Qualitative interviews with care partners about their engagement in discussions of “off” periods
Health Expectations. 22(3):555-564 [DOI] 10.1111/hex.12884. [PMID] 30977262.
2019
Lewy Body Dementias
Continuum (Minneapolis, Minn.). 25(1):128-146 [DOI] 10.1212/CON.0000000000000685. [PMID] 30707190.
2019
Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing.
Alzheimer disease and associated disorders. 33(3):246-253 [DOI] 10.1097/WAD.0000000000000311. [PMID] 31058683.
2019
Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 93(13):584-594 [DOI] 10.1212/WNL.0000000000008157. [PMID] 31462584.
2019
Recognizing and treating atypical Parkinson disorders.
Handbook of clinical neurology. 167:301-320 [DOI] 10.1016/B978-0-12-804766-8.00016-9. [PMID] 31753139.
2019
Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson’s Disease
Dementia and Geriatric Cognitive Disorders. 47(4-6):187-197 [DOI] 10.1159/000496454. [PMID] 31315127.
2019
Shared decision making in mild cognitive impairment.
Neurology. Clinical practice. 9(2):160-164 [DOI] 10.1212/CPJ.0000000000000576. [PMID] 31041132.
2019
Tackling the imposter phenomenon to advance women in neurology.
Neurology. Clinical practice. 9(2):155-159 [DOI] 10.1212/CPJ.0000000000000607. [PMID] 31041131.
2019
The Clinician Guideline Determinants Questionnaire was developed and validated to support tailored implementation planning.
Journal of clinical epidemiology. 113:129-136 [DOI] 10.1016/j.jclinepi.2019.05.024. [PMID] 31152863.
2019
The experience of off periods: Qualitative analysis of interviews with persons with Parkinson’s and carepartners.
Clinical parkinsonism & related disorders. 1:31-36 [DOI] 10.1016/j.prdoa.2019.07.008. [PMID] 34316596.
2019
The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease
JAMA neurology. 77(3):295-297 [DOI] 10.1001/jamaneurol.2019.3983. [PMID] 31841588.
2019
Virtual Support Groups for Informal Caregivers of Individuals With Dementia: A Scoping Review.
Alzheimer disease and associated disorders. 33(4):362-369 [DOI] 10.1097/WAD.0000000000000349. [PMID] 31567144.
2018
Approach to assessing and using clinical practice guidelines.
Neurology. Clinical practice. 8(1):58-61 [DOI] 10.1212/CPJ.0000000000000417. [PMID] 29517067.
2018
Author response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 91(8):373-374 [DOI] 10.1212/WNL.0000000000006042. [PMID] 30126885.
2018
Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 90(10):464-471 [DOI] 10.1212/WNL.0000000000005055. [PMID] 29440566.
2018
Comprehensive systematic review update summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research.
Neurology. 91(10):461-470 [DOI] 10.1212/WNL.0000000000005928. [PMID] 30089617.
2018
Comprehensive Systematic Review Update Summary: Disorders of Consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research.
Archives of physical medicine and rehabilitation. 99(9):1710-1719 [DOI] 10.1016/j.apmr.2018.07.002. [PMID] 30098792.
2018
Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 91(20):923-933 [DOI] 10.1212/WNL.0000000000006502. [PMID] 30315070.
2018
Identifying priority outcomes that influence selection of disease-modifying therapies in MS.
Neurology. Clinical practice. 8(3):179-185 [DOI] 10.1212/CPJ.0000000000000449. [PMID] 30105155.
2018
Impact of patient involvement on clinical practice guideline development: a parallel group study
Implementation Science. 13(1) [DOI] 10.1186/s13012-018-0745-6. [PMID] 29661195.
2018
Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research.
Neurology. 91(10):450-460 [DOI] 10.1212/WNL.0000000000005926. [PMID] 30089618.
2018
Practice Guideline Update Recommendations Summary: Disorders of Consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research.
Archives of physical medicine and rehabilitation. 99(9):1699-1709 [DOI] 10.1016/j.apmr.2018.07.001. [PMID] 30098791.
2018
Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 90(3):126-135 [DOI] 10.1212/WNL.0000000000004826. [PMID] 29282327.
2018
Progressive Supranuclear Palsy: an Update.
Current neurology and neuroscience reports. 18(3) [DOI] 10.1007/s11910-018-0819-5. [PMID] 29455271.
2018
Understanding, Impact, and Communication of “Off” Periods in Parkinson’s Disease: A Scoping Review
Movement Disorders Clinical Practice. 5(5):461-470 [DOI] 10.1002/mdc3.12672. [PMID] 30515435.
2017
Author response: Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 88(24):2337-2338 [DOI] 10.1212/WNL.0000000000004047. [PMID] 28607140.
2017
Dementia with Lewy bodies advances: A new consensus report.
Neurology. 89(1):18-19 [DOI] 10.1212/WNL.0000000000004071. [PMID] 28592452.
2017
Discordance Between Physician Assessment and Patient-Reported Depressive Symptoms in Parkinson Disease
Journal of Geriatric Psychiatry and Neurology. 30(4):191-195 [DOI] 10.1177/0891988717710335.
2017
Framework for enhancing clinical practice guidelines through continuous patient engagement.
Health expectations : an international journal of public participation in health care and health policy. 20(1):3-10 [DOI] 10.1111/hex.12467. [PMID] 27115476.
2017
Hospitalization and Rehospitalization in Parkinson Disease Patients: Data From the National Parkinson Foundation Centers of Excellence
PLoS One. 12(7) [DOI] 10.1371/purnal.pone.0180425.
2017
Hospitalization and rehospitalization in Parkinson disease patients: Data from the National Parkinson Foundation Centers of Excellence.
PloS one. 12(7) [DOI] 10.1371/journal.pone.0180425. [PMID] 28683150.
2017
Improving email strategies to target stress and productivity in clinical practice.
Neurology. Clinical practice. 7(6):512-517 [DOI] 10.1212/CPJ.0000000000000395. [PMID] 29431178.
2017
Naturalistic study of guideline implementation tool use via evaluation of website access and physician survey.
BMC medical informatics and decision making. 17(1) [DOI] 10.1186/s12911-016-0404-2. [PMID] 28086771.
2017
Patient involvement in guidelines is poor five years after institute of medicine standards: review of guideline methodologies.
Research involvement and engagement. 3 [DOI] 10.1186/s40900-017-0070-2. [PMID] 29062544.
2017
Practice guideline summary: Reducing brain injury following cardiopulmonary resuscitation: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 88(22):2141-2149 [DOI] 10.1212/WNL.0000000000003966. [PMID] 28490655.
2017
Recommendations for Patient Engagement in Guideline Development Panels: a Qualitative Focus Group Study of Guideline-Naive Patients
PLoS One. 12(3) [DOI] 10.1371/journal.pone.0114329. [PMID] 25474207.
2017
Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naïve patients
PLOS ONE. 12(3) [DOI] 10.1371/journal.pone.0174329. [PMID] 28319201.
2017
Rehabilitation in multiple sclerosis: Commentary on the recent AAN systematic review.
Neurology. Clinical practice. 7(3):189-190 [DOI] 10.1212/01.CPJ.0000520916.56328.f5. [PMID] 30128173.
2017
Response shift – The experience of disease progression in Parkinson disease.
Parkinsonism & related disorders. 36:52-56 [DOI] 10.1016/j.parkreldis.2016.12.027. [PMID] 28082015.
2017
Shared decision-making in stroke: an evolving approach to improved patient care
Stroke and Vascular Neurology. 2(2):84-87 [DOI] 10.1136/svn-2017-000081. [PMID] 28959495.
2017
The Case for Antipsychotics in Dementia with Lewy Bodies.
Movement disorders clinical practice. 4(1):32-35 [DOI] 10.1002/mdc3.12383. [PMID] 30713945.
2017
Use of theory to plan or evaluate guideline implementation among physicians: a scoping review.
Implementation science : IS. 12(1) [DOI] 10.1186/s13012-017-0557-0. [PMID] 28241771.
2017
Value Assessment at the Point of Care: Incorporating Patient Values throughout Care Delivery and a Draft Taxonomy of Patient Values.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20(2):292-295 [DOI] 10.1016/j.jval.2016.11.008. [PMID] 28237212.
2016
Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive-Compulsive Behaviors.
Movement disorders clinical practice. 3(4):412-414 [DOI] 10.1002/mdc3.12299. [PMID] 30713933.
2016
Patient engagement and shared decision-making: What do they look like in neurology practice?
Neurology. Clinical practice. 6(2):190-197 [PMID] 27104070.
View on: PubMed
2016
Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 87(24):2585-2593 [PMID] 27856776.
View on: PubMed
2016
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Neurology. 86(19):1818-26 [DOI] 10.1212/WNL.0000000000002560. [PMID] 27164716.
2016
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 87(6) [DOI] 10.1212/01.wnl.0000491123.28224.44. [PMID] 27502965.
2015
Does spouse participation influence quality of life reporting in patients with Parkinson’s disease?
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 24(1):245-9 [DOI] 10.1007/s11136-014-0744-2. [PMID] 24972974.
2015
Extracorporeal membrane oxygenation: uncommon cause of corpus callosal microhemorrhage.
Neurology. 84(6) [DOI] 10.1212/WNL.0000000000001227. [PMID] 25666630.
2015
Independent application of montreal cognitive assessment/mini-mental state examination conversion.
Movement disorders : official journal of the Movement Disorder Society. 30(12):1710-1 [DOI] 10.1002/mds.26221. [PMID] 25820874.
2015
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Neurology. 85(21):1896-903 [DOI] 10.1212/WNL.0000000000002146. [PMID] 26598432.
2014
“Rapidly” Progressive Supranuclear Palsy.
Movement disorders clinical practice. 1(1):70-72 [DOI] 10.1002/mdc3.12011. [PMID] 30363883.
2014
Author response.
Neurology. 82(1) [PMID] 24520569.
View on: PubMed
2014
Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson’s Disease?
Movement disorders clinical practice. 1(1):67-69 [DOI] 10.1002/mdc3.12009. [PMID] 30363792.
2014
Diagnosis and treatment of corticobasal degeneration.
Current treatment options in neurology. 16(3) [DOI] 10.1007/s11940-013-0282-1. [PMID] 24469408.
2014
Which features of Parkinson’s disease predict earlier exit from the workforce?
Parkinsonism & related disorders. 20(11):1257-9 [DOI] 10.1016/j.parkreldis.2014.08.005. [PMID] 25179494.
2013
Author Response.
Neurology. 80(10) [PMID] 23580968.
View on: PubMed
2013
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
Journal of neurology, neurosurgery, and psychiatry. 84(2):130-5 [DOI] 10.1136/jnnp-2012-302684. [PMID] 22933817.
2013
Clinicopathological review of pallidonigroluysian atrophy.
Movement disorders : official journal of the Movement Disorder Society. 28(3):274-81 [DOI] 10.1002/mds.25232. [PMID] 23114877.
2013
Criteria for the diagnosis of corticobasal degeneration.
Neurology. 80(5):496-503 [DOI] 10.1212/WNL.0b013e31827f0fd1. [PMID] 23359374.
2013
Impact of mild cognitive impairment on health-related quality of life in Parkinson’s disease.
Dementia and geriatric cognitive disorders. 36(1-2):67-75 [DOI] 10.1159/000350032. [PMID] 23774742.
2013
Measuring mild cognitive impairment in patients with Parkinson’s disease.
Movement disorders : official journal of the Movement Disorder Society. 28(5):626-33 [DOI] 10.1002/mds.25426. [PMID] 23520128.
2013
Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology.
Neurology. 80(22):2065-9 [DOI] 10.1212/WNL.0b013e318294b32d. [PMID] 23713086.
2013
The American Academy of Neurology’s top five choosing wisely recommendations.
Neurology. 81(11):1004-11 [DOI] 10.1212/WNL.0b013e31828aab14. [PMID] 23430685.
2013
The meaning of a “hippo” response on the Montreal Cognitive Assessment in Parkinson’s disease.
Parkinsonism & related disorders. 19(4):463-5 [DOI] 10.1016/j.parkreldis.2012.09.005. [PMID] 23036511.
2012
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
Neurology. 79(6):597-603 [DOI] 10.1212/WNL.0b013e318263c443. [PMID] 22815556.
2012
Improvement of apathy after levofloxacin treatment: an N-of-1 study.
The neurologist. 18(3):146-8 [DOI] 10.1097/NRL.0b013e318251eb23. [PMID] 22549356.
2012
Roles of Education and IQ in Cognitive Reserve in Parkinson’s Disease-Mild Cognitive Impairment.
Dementia and geriatric cognitive disorders extra. 2(1):343-52 [DOI] 10.1159/000341782. [PMID] 22962558.
2012
The pill questionnaire in a nondemented Parkinson’s disease population.
Movement disorders : official journal of the Movement Disorder Society. 27(10):1308-11 [DOI] 10.1002/mds.25124. [PMID] 22865587.
2011
Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia.
Movement disorders : official journal of the Movement Disorder Society. 26(12):2296-7 [DOI] 10.1002/mds.23822. [PMID] 21714005.
2009
Cerebroretinal microangiopathy with calcifications and cysts: demonstration of radiological progression.
Journal of computer assisted tomography. 33(4):571-2 [DOI] 10.1097/RCT.0b013e31818c0957. [PMID] 19638852.
2006
Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients.
Neurologic clinics. 24(4):607-30 [PMID] 16935191.
View on: PubMed
2006
Thoracic intramedullary cavernous malformation with posttraumatic hematomyelia: case report and literature review.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 15(2):74-8 [PMID] 17904054.
View on: PubMed
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
. [DOI] 10.20944/preprints202109.0133.v1.

Grants

Sep 2021 ACTIVE
Multi-Stakeholder Engagement for Interdisciplinary Telehealth in Lewy Body Dementia
Role: Other
Funding: NATL INST OF HLTH NIA
Jan 2021 ACTIVE
Delirium-onset Lewy body biomarkers
Role: Other
Funding: UF FOUNDATION
Jan 2021 ACTIVE
Characterizing Cognitive Fluctuations in Lewy Body Dementia to Improve Care and Research
Role: Other
Funding: UF FOUNDATION
Sep 2020 ACTIVE
Identifying Factors Predicting ACcurately End-of-Life in Dementia with Lewy Bodies and Promoting Quality End-of-Life Experiences: the PACE-DLB Study
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Sep 2020 ACTIVE
F022983 – UF Parkinson's Disease/Movement Disorders Fund
Role: Principal Investigator
Funding: UF FOUNDATION
Jun 2020 ACTIVE
1Florida Alzheimers Disease Research Center
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
May 2020 ACTIVE
Communication of Dementia Diagnoses: Investigating Patient, Family, and Physician Experiences and Developing Best Practices
Role: Principal Investigator
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Feb 2020 – May 2020
Prevalence and Demographics of Multiple Sclerosis in the OneFlorida Data Trust
Role: Other
Funding: NATL MULTIPLE SCLEROSIS SOC
Jan 2020 ACTIVE
Lewy Body Dementia: Mangurian
Role: Principal Investigator
Funding: UF FOUNDATION
Oct 2019 ACTIVE
LBDA RCOE Program
Role: Principal Investigator
Funding: LEWY BODY DEMENTIA ASSOC
Oct 2018 – Sep 2019
University of Florida Collaboration as LBDA Research Center of Excellence- Year 2
Role: Principal Investigator
Funding: LEWY BODY DEMENTIA ASSOC
Jul 2018 – Jun 2020
Investigating Patterns of Care for Dementia with Lewy Bodies in Florida
Role: Other
Funding: AMER ACAD OF NEUROLOGY
Oct 2017 – Sep 2018
University of Florida Collaboration as LBDA Research Center of Excellence
Role: Principal Investigator
Funding: LEWY BODY DEMENTIA ASSOC
Sep 2015 – Jun 2020
Enhancing Clinical Guideline Development via Patient and Stakeholder
Role: Principal Investigator
Funding: AGCY HEALTHCARE RES AND QUALITY
Aug 2015 – May 2021
University of Florida – Mt. Sinai Medical Center AD Research Center
Role: Project Manager
Funding: NATL INST OF HLTH NIA

Education

MD
2003 · Loyola University Medical Center

Teaching Profile

Courses Taught
2021
MDC7800 Neurology Clerkship

Contact Details

Phones:
Business:
(352) 273-5550